Patients enrolled in high-deductible health insurance plans have lower rates of use and lower costs for imaging tests, suggests a study in the February issue of Medical Care.

At the beginning of each year, I always try to determine what the next big cardiovascular technology advances to watch will be in the coming 12 months.  I did not have to look far, as the U.S. Food and Drug Administration (FDA) has pretty much outlined four of these advances with recent meeting notices and approval of a new clinical trial. 

A lengthy review of increasing medical evidence shows that cancer treatments such as chemotherapy and radiation often damage heart vessels and tissues, increasing the risk of later heart disease in cancer survivors. Now an interventional cardiologist from Detroit Medical Center (DMC) who is a co-author of the study is helping efforts to expand a new medical specialty known as “cardioncology.”

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer recommendations concerning the final approval of Abbott’s Absorb fully bioresorbable stent and the AngelMed Guardian System.

A group of researchers from Russia, Australia and the Netherlands have developed a technology that can reduce magnetic resonance imaging (MRI) scanning times by more than 50 percent.

Bradycardia – a slower than normal heartbeat – does not increase the risk of developing cardiovascular disease, according to a study conducted by researchers at Wake Forest Baptist Medical Center. The study is published in the Jan.19 online edition of the Journal of American Medical Association Internal Medicine.

Global Genomics Group (G3) and GNS Healthcare (GNS), announced preliminary results of the GLOBAL Clinical Study designed to identify biomarkers associated with coronary artery disease (CAD). The study provided proof of concept of the approach by prospectively identifying a biochemical pathway known to be associated with CAD.

Vivasure Medical announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable percutaneous vascular closure device for large-bore femoral arteriotomies.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now